|
 |
||||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals to Present at American Stock Exchange Annual Online Healthcare & Biotech Investor Conference SAN DIEGO – June 21, 2004 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it will participate in the American Stock Exchange Annual Online Healthcare & Biotech Investor Conference on Tuesday, June 22, 2004. Nicholas Jon Virca, President & CEO, is scheduled to present at 12:00 p.m. EDT. Interested parties may listen to the live or archived webcast by accessing www.vcall.com/CEPage.asp?ID=88408. A link to the webcast will also be available for the next 45 days on the ADVENTRX website at www.adventrx.com. For a complete agenda of the American Stock Exchange and Amex IR Alliance Online Conference, please visit www.vcallconferences.com/conferences/AMEX/0622-29-2004/index.asp?ID=88206. Minimum requirements to listen to broadcast: Windows Media Player software, downloadable free from microsoft.com/windows/windowsmedia/EN/, and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, please send an email to webmaster@vcall.com. About ADVENTRX ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information on ADVENTRX can be found on the Company's website at www.adventrx.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contacts: The Ruth Group Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac, Ph.D. 646-536-7028 |
